Recursion 2026年第一季度每股收益（EPS）为-0.22美元，超出市场预期的-0.26美元；但营收表现不佳，录得647万美元，远低于市场预期的1628万美元，差距高达60.26%。 受喜忧参半的业绩和营收大幅不及预期的影响，公司股价在盘前交易中下跌1.84%，报3.20美元。 公司将现金运营支出同比削减了30%；并维持6.65亿美元的现金头寸，这将公司财务跑道延长至2028年初。 公司 ...

Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash ...

Recursion Pharmaceuticals, Inc. is advancing REC-1245, an RBM39 degrader, in the DHALIA trial in solid tumors. Read more on ...

Recursion Pharmaceuticals (RXRX) is back in focus as investors weigh fresh updates on its AI-driven drug discovery platform, along with progress in key clinical assets REC-1245 and REC-4881 and ...

The stock looks cheap, but appearances can be deceiving.

View Recursion Pharmaceuticals, Inc. Class A RXRX stock quote prices, financial information, real-time forecasts, and company news from CNN.

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the 9 Stocks Crushing the Market With Surging Returns. Recursion ...

Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on May 26, 2026, the Compensation Committee of Recursion's Board of ...

Recursion Pharmaceuticals, a drug discovery company that applies artificial intelligence to biology, is shoring up its technology platform by buying two startups that bolster its chemistry ...

Salt Lake City, UT, June 02, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation ...

Everything touching artificial intelligence (AI) is hot right now, so it's no surprise that the biotech Recursion Pharmaceuticals (NASDAQ: RXRX) could be positioned to ride the ongoing wave of hype to ...